1 – 7 of 7
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer’s disease
(
- Contribution to journal › Article
- 2023
-
Mark
Confounding factors of Alzheimer's disease plasma biomarkers and their impact on clinical performance
(
- Contribution to journal › Article
-
Mark
Plasma p-tau217 predicts in vivo brain pathology and cognition in autosomal dominant Alzheimer's disease
(
- Contribution to journal › Article
- 2022
-
Mark
Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer’s dementia in mild cognitive impairment patients
(
- Contribution to journal › Article
-
Mark
Serum Neurofilament Light Chain as a Marker of Progression in Parkinson's Disease : Long-Term Observation and Implications of Clinical Subtypes
(
- Contribution to journal › Article
- 2017
-
Mark
Increased blood-brain barrier permeability is associated with dementia and diabetes but not amyloid pathology or APOE genotype
(
- Contribution to journal › Article
-
Mark
CSF/serum albumin ratio in dementias : a cross-sectional study on 1861 patients
(
- Contribution to journal › Article